Stanford Medicine Researchers Uncover Novel Appetite-Suppressing Molecule with Potential to Outperform Semaglutide
Stanford Medicine researchers have identified a naturally occurring molecule that may suppress appetite and reduce body weight in a way that resembles semaglutide, the active ingredient in Ozempic. In animal studies, the molecule also appeared to avoid several problems associated with the drug, including nausea, constipation and substantial muscle loss. This groundbreaking discovery, detailed in the prestigious journal Nature, could pave the way for a new generation of obesity and metabolic disorder treatments, potentially offering a more targeted and tolerable alternative to existing therapies.
The molecule, designated BRP (BRINP2-related-peptide), operates through a distinct yet related metabolic pathway, activating a separate set of neurons within the brain. This crucial difference from semaglutide, which targets receptors found throughout the brain and digestive system, suggests BRP could offer a more precise mechanism for appetite and weight management, minimizing the widespread side effects often associated with current weight-loss medications.
A New Frontier in Appetite Regulation
The hypothalamus, a small but critical region deep within the brain, serves as the body’s central regulator for hunger, thirst, body temperature, hormone activity, and overall energy expenditure. It is this specific area that BRP appears to primarily influence. Assistant Professor of Pathology Katrin Svensson, PhD, the senior author of the study, explained the significance of this targeted action. "The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues," Dr. Svensson stated. "That’s why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."
This localized effect is particularly promising, as it suggests BRP could modulate appetite signals without triggering the cascade of systemic effects that often lead to gastrointestinal distress, such as nausea and constipation, and significant muscle mass reduction, which are common challenges for individuals using semaglutide and other GLP-1 receptor agonists.
The implications of this discovery are substantial, given the global obesity epidemic. The World Health Organization (WHO) estimates that over 1 billion people worldwide are obese, with projections indicating a continued rise in these figures. Effective and safe treatments are desperately needed, and the potential for a molecule that mimics the efficacy of semaglutide while mitigating its drawbacks presents a significant advancement.
The Power of Artificial Intelligence in Peptide Discovery
The identification of BRP was not a serendipitous find but a triumph of modern scientific methodology, heavily reliant on artificial intelligence (AI). The research team employed a sophisticated AI-driven approach to sift through the complex landscape of prohormones, which are inactive precursor molecules that are later cleaved by enzymes into active peptides.
Prohormones are the genetic blueprints for a vast array of signaling molecules, including hormones that regulate critical bodily functions. However, the process of enzyme-mediated cleavage can produce a multitude of fragments, making it challenging to pinpoint the truly biologically active peptides. Traditional laboratory techniques, while effective, can generate enormous datasets, requiring researchers to meticulously analyze hundreds of thousands of molecules to identify those with meaningful physiological effects.
The research team focused their attention on a specific enzyme, prohormone convertase 1/3 (PC1/3), which is known to cleave prohormones at particular amino acid sequences. This enzyme has previously been linked to human obesity, making it a prime target for investigation. It is also the enzyme responsible for producing glucagon-like peptide 1 (GLP-1), the very peptide that semaglutide emulates.
The researchers hypothesized that PC1/3 might also generate other peptides with significant roles in energy balance and appetite regulation. To explore this possibility, they developed an AI-powered computational tool named "Peptide Predictor."
Peptide Predictor: A Digital Detective for Hidden Signals
Instead of embarking on laborious manual extraction and analysis of proteins and peptides from biological tissues, the Stanford team leveraged AI to accelerate their search. Peptide Predictor was designed to scan all 20,000 human protein-coding genes, identifying potential cleavage sites where PC1/3 enzymes typically act. The algorithm further refined its search by prioritizing genes that produce proteins secreted outside the cell—a common characteristic of hormones—and that contained at least four potential cleavage sites.
This intelligent filtering process dramatically narrowed down the field of investigation from tens of thousands of genes to a more manageable 373 prohormones. "The algorithm was absolutely key to our findings," Dr. Svensson emphasized, highlighting the transformative impact of AI on their research capabilities.
Peptide Predictor estimated that PC1/3 could generate an impressive 2,683 distinct peptides from these 373 prohormones. Drs. Coassolo and Svensson then focused their efforts on sequences that exhibited the highest probability of influencing brain function related to metabolism and appetite.
They ultimately selected 100 peptides, including the well-known GLP-1, for laboratory testing. These peptides were assessed for their ability to stimulate neuron-like cells cultured in vitro.
BRP Emerges: A Potent Appetite Suppressor
The initial cell-based assays yielded compelling results. As anticipated, GLP-1 demonstrated a robust activation of the neuronal cells, increasing their activity threefold compared to untreated control cells. However, one much smaller peptide, BRP, produced an even more striking response. Composed of only 12 amino acids, BRP amplified neuronal activity by a remarkable tenfold increase compared to controls.
This tiny peptide, derived from the parent prohormone BPM/retinoic acid inducible neural specific 2 (BRINP2), exhibited an outsized effect, underscoring the principle that size is not always indicative of potency in biological signaling.
Preclinical Efficacy: Promising Results in Animal Models
Following the promising in vitro findings, the researchers advanced their investigation to animal models. They tested BRP in both lean mice and minipigs, the latter chosen for their metabolic and eating patterns that more closely mirror those of humans than mice.
In a critical experiment, an intramuscular injection of BRP administered before feeding led to a significant reduction in food intake, with some animals consuming up to 50% less in the subsequent hour in both species. This demonstrates a potent and immediate appetite-suppressing effect.
Furthermore, daily BRP injections were administered to obese mice over a 14-day period. The results were highly encouraging: treated animals experienced an average weight loss of 3 grams, with nearly all of this reduction attributed to body fat. In stark contrast, the control group of obese mice gained approximately 3 grams during the same timeframe.
Beyond weight loss, the BRP-treated mice also exhibited improvements in glucose and insulin tolerance. These metabolic markers are crucial indicators of how effectively the body manages blood sugar and responds to insulin, the hormone essential for glucose uptake by cells. Improved tolerance suggests a positive impact on metabolic health, a critical consideration for individuals with or at risk of type 2 diabetes.
Mitigating Side Effects: A Key Advantage
A significant aspect of the BRP research centers on its apparent lack of common side effects associated with existing weight-loss medications. Behavioral assessments in the animal studies revealed no meaningful differences between BRP-treated and untreated animals in terms of movement, water consumption, anxiety-like behavior, or fecal production.
The absence of changes in fecal production is particularly noteworthy, as constipation is a well-documented side effect of semaglutide, stemming from its action of slowing gastrointestinal transit. Similarly, the researchers did not observe any indications of nausea-related responses or the substantial muscle loss that can occur with some weight-loss interventions.
Additional physiological measurements confirmed that BRP acts through distinct metabolic and neuronal pathways compared to GLP-1 and semaglutide. This suggests that BRP’s appetite-suppressing effects are mediated by a more specialized biological route, potentially explaining its improved side effect profile, although these findings remain preliminary and confined to animal studies.
The Road Ahead: Clinical Trials and Future Directions
While the preclinical results are highly promising, the journey from laboratory discovery to human application involves rigorous further investigation. Dr. Svensson and her colleagues have co-founded a company with the explicit aim of initiating human clinical trials for BRP in the near future.
Several key questions remain to be addressed before BRP can be considered for widespread clinical use. The researchers are actively working to identify the specific cell-surface receptors to which BRP binds. Understanding these receptor interactions is paramount for fully elucidating how the peptide influences appetite and metabolism. "The researchers are now working to identify the cell-surface receptors that attach to BRP," the study notes. "Receptors are molecular structures that receive signals from hormones, drugs, and other chemical messengers. Determining which receptor BRP uses will help scientists understand exactly how the peptide changes appetite and metabolism."
Furthermore, the team aims to map the complete sequence of biological events that unfold after BRP binds to its target receptor. This detailed understanding will be crucial for optimizing its therapeutic potential and identifying any unforeseen interactions.
Another critical challenge for small peptides like BRP is their duration of action. Many small peptides are rapidly degraded by the body, which can limit their therapeutic efficacy and necessitate frequent administration. The researchers are exploring strategies to enhance BRP’s stability and prolong its effects, aiming for a dosing schedule that is practical for patients.
"The lack of effective drugs to treat obesity in humans has been a problem for decades," Dr. Svensson remarked. "Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."
The research was supported by significant funding from the National Institutes of Health (NIH) and various Stanford University initiatives, including the SPARK Translational Research Program, Stanford Bio-X, and the Stanford Maternal and Child Health Research Institute. Additional contributions came from the American Heart Association, a Stanford Medicine Dean’s Fellowship Award, the Carlsberg Foundation, and the Wu Tsai Human Performance Alliance.
Drs. Svensson and Coassolo are listed as inventors on patents related to BRP peptides for metabolic disorders, and Dr. Svensson is a co-founder of Merrifield Therapeutics, the company poised to lead the upcoming human trials. Collaborations with researchers from the University of California, Berkeley; the University of Minnesota; and the University of British Columbia were also instrumental in this multifaceted study.
The successful translation of BRP from preclinical promise to a clinically viable treatment could represent a significant leap forward in addressing the complex and pervasive challenges of obesity and metabolic disease, offering hope for millions worldwide seeking more effective and tolerable weight management solutions.
